Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization (2016 - 2023)

Spyre Therapeutics' Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $744000.0 for Q4 2023.

  • For Q4 2023, Accumulated Depreciation & Amortization fell 52.52% year-over-year to $744000.0; the TTM value through Dec 2023 reached $744000.0, down 52.52%, while the annual FY2023 figure was $744000.0, 52.52% down from the prior year.
  • Accumulated Depreciation & Amortization reached $744000.0 in Q4 2023 per SYRE's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.0 million in Q4 2020 to a low of $744000.0 in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.4 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 87.96% in 2020, then plummeted 52.52% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then decreased by 20.52% to $1.6 million in 2021, then fell by 0.57% to $1.6 million in 2022, then tumbled by 52.52% to $744000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Accumulated Depreciation & Amortization are $744000.0 (Q4 2023), $1.6 million (Q4 2022), and $1.6 million (Q4 2021).